TherapeuticsMD (NASDAQ:TXMD) Price Target Cut to $3.00 by Analysts at Jefferies Financial Group

TherapeuticsMD (NASDAQ:TXMD) had its price objective cut by Jefferies Financial Group from $4.00 to $3.00 in a report published on Monday morning, The Fly reports. They currently have a hold rating on the stock. Jefferies Financial Group also issued estimates for TherapeuticsMD’s Q2 2019 earnings at ($0.18) EPS, Q3 2019 earnings at ($0.18) EPS, Q4 2019 earnings at ($0.25) EPS, FY2019 earnings at ($0.75) EPS, FY2020 earnings at ($0.53) EPS, FY2021 earnings at $0.08 EPS, FY2022 earnings at $1.02 EPS and FY2023 earnings at $1.16 EPS.

Several other brokerages have also recently issued reports on TXMD. Oppenheimer set a $12.00 price objective on CymaBay Therapeutics and gave the company a buy rating in a research note on Tuesday, June 11th. Zacks Investment Research cut Hess Midstream Partners from a hold rating to a sell rating in a research note on Tuesday, May 14th. ValuEngine upgraded Vermillion from a hold rating to a buy rating in a research note on Wednesday, May 15th. Cowen cut their price objective on TherapeuticsMD from $16.00 to $9.00 and set an outperform rating on the stock in a research note on Tuesday, June 11th. Finally, BidaskClub upgraded Winmark from a sell rating to a hold rating in a research note on Tuesday, May 14th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $9.28.

NASDAQ:TXMD opened at $2.27 on Monday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 3.28 and a current ratio of 3.39. TherapeuticsMD has a one year low of $2.21 and a one year high of $6.94. The stock has a 50-day simple moving average of $2.70. The firm has a market capitalization of $559.63 million, a PE ratio of -3.85 and a beta of 1.88.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Monday, May 6th. The company reported ($0.16) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.01. TherapeuticsMD had a negative return on equity of 159.71% and a negative net margin of 907.71%. The business had revenue of $3.95 million for the quarter, compared to analysts’ expectations of $5.96 million. During the same quarter in the previous year, the firm posted ($0.11) earnings per share. The company’s revenue was up 4.8% compared to the same quarter last year. As a group, equities research analysts expect that TherapeuticsMD will post -0.69 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Moors & Cabot Inc. purchased a new stake in shares of TherapeuticsMD in the second quarter valued at $25,000. FMR LLC lifted its holdings in shares of TherapeuticsMD by 0.5% in the first quarter. FMR LLC now owns 18,178,211 shares of the company’s stock valued at $88,527,000 after purchasing an additional 89,870 shares in the last quarter. Metropolitan Life Insurance Co NY lifted its holdings in shares of TherapeuticsMD by 8.2% in the first quarter. Metropolitan Life Insurance Co NY now owns 60,906 shares of the company’s stock valued at $296,000 after purchasing an additional 4,627 shares in the last quarter. Rubric Capital Management LP raised its holdings in shares of TherapeuticsMD by 203.6% during the first quarter. Rubric Capital Management LP now owns 4,690,970 shares of the company’s stock worth $22,845,000 after acquiring an additional 3,145,742 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale raised its holdings in shares of TherapeuticsMD by 22.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 87,500 shares of the company’s stock worth $564,000 after acquiring an additional 16,000 shares in the last quarter. Hedge funds and other institutional investors own 78.93% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

Further Reading: What are earnings reports?

The Fly

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.